ライフサイエンスコーパス: acute hepatitis C

1 longitudinally from the time of diagnosis of acute hepatitis C.

2 egylated interferon alfa-2b for treatment of acute hepatitis C.

3 as playing a critical role in the outcome of acute hepatitis C.

4 We identified 20 participants with acute hepatitis C (10 with hepatitis C virus [HCV] monoi

5 to develop chronic hepatitis than those with acute hepatitis C (23% vs. 68%; P < .05).

6 Of 45 patients with acute hepatitis C, 40.0% were simultaneously infected wi

7 Therapy of acute hepatitis C (AHC) has not yet been standardized an

8 Treatment of patients with acute hepatitis C (AHC) is more effective, with sustaine

9 ortion of HIV(+) patients manage to overcome acute hepatitis C (AHC) spontaneously.

10 ease resolution in a cohort of patients with acute hepatitis C (AHC), analyzing epidemiological, clin

11 els of IP-10, with outcomes of patients with acute hepatitis C (AHC).

12 We examined trends in incidence of acute hepatitis C among young persons reported to the Ce

13 Hepatitis C virus (HCV) causes acute hepatitis C and can lead to life-threatening compl

14 e epidemiologically distinct from those with acute hepatitis C and have a significantly more severe a

15 are essential for spontaneous resolution of acute hepatitis C and long-term protection from persiste

16 emed essential for spontaneous resolution of acute hepatitis C and long-term protection.

17 Patients with acute hepatitis C and schistosomiasis coinfection cannot

18 Acute hepatitis C and spontaneous clearance was also ass

19 Acute hepatitis C and spontaneous clearance was associat

20 ants identified from the Australian Trial in Acute Hepatitis C and the Networks study were followed l

21 cal correlates of clearance in patients with acute hepatitis C and their sexual contacts.

22 Further, PBMC from patients with acute hepatitis C as well as HCV-infected Huh7.5 cells h

23 The Australian Trial in Acute Hepatitis C (ATAHC) was a prospective study of the

24 ubjects, enrolled in the Australian Trial in Acute Hepatitis C (ATAHC), using HCV peptide enzyme-link

25 markedly prolonged the incubation period of acute hepatitis C but did not prevent or delay HCV infec

26 covery occurs in a minority of patients with acute hepatitis C but is associated with vigorous and lo

27 Clinically, acute hepatitis C can increase concentrations of alanine

28 ceptor (TLR) expression and signaling during acute hepatitis C correlates with clinical outcomes.

29 Approximately 85% of persons with acute hepatitis C develop chronic hepatitis as determine

30 nclude that approximately 85% of people with acute hepatitis C develop persistent viremia.

31 Acute hepatitis C developed in both the IGIV-treated and

32 ells from healthy controls and patients with acute hepatitis C efficiently recognized both HCV-infect

33 Although the incidence of acute hepatitis C has declined, there is a large reservo

34 Approximately three quarters of acute hepatitis C (HCV) infections evolve to a chronic s

35 virin and also with spontaneous clearance of acute hepatitis C in a heterogeneous population.

36 d the efficacy of PEG IFN-alpha treatment in acute hepatitis C in relation to the kinetics of hepatit

37 mately 10% of persons with reported cases of acute hepatitis C in the United States report a history

38 Reports of acute hepatitis C in young persons in the United States

39 From 2006 to 2012, reported incidence of acute hepatitis C increased significantly in young perso

40 Peginterferon alfa-2b monotherapy in acute hepatitis C induces high sustained virologic respo

41 s with FPAs were compared with patients with acute hepatitis C infection without FPAs.

42 In acute hepatitis C infection, close monitoring of hepatit

43 There is a paucity of information on core in acute hepatitis C infection.

44 od samples from participants in the Montreal Acute Hepatitis C Injection Drug User Cohort Study who w

45 Our results show that the outcome of acute hepatitis C is associated with a functional hierar

46 The outcome of acute hepatitis C is associated with efficient virus-spe

47 Acute hepatitis C is marked by appearance of HCV RNA in

48 Acute hepatitis C is most often diagnosed in the setting

49 chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action

50 Mechanisms by which spontaneous clearance of acute hepatitis C occurs are unclear.

51 Symptomatic acute hepatitis C occurs in only about 15% of patients w

52 A patient developed acute hepatitis C shortly after tissue transplantation.

53 se of an activated NK cell population during acute hepatitis C, that is largely restored upon viral c

54 Compared with patients with acute hepatitis C, those with non-ABCDE hepatitis had a

55 ve used this resource to study parameters of acute hepatitis C virus (HCV) infection among 94 donor-r

56 r (NK) cells likely contribute to outcome of acute hepatitis C virus (HCV) infection and interferon (

57 e a patient with hypogammaglobulinemia whose acute hepatitis C virus (HCV) infection appeared to reso

58 Outbreaks of acute hepatitis C virus (HCV) infection are occurring in

59 Acute hepatitis C virus (HCV) infection becomes chronic

60 Acute hepatitis C virus (HCV) infection culminates in vi

61 Although 20%-40% of persons with acute hepatitis C virus (HCV) infection demonstrate spon

62 Since 2002, a global epidemic of acute hepatitis C virus (HCV) infection has been noted i

63 sequelae during the first two decades after acute hepatitis C virus (HCV) infection have been well s

64 tween IL28B and the clinical presentation of acute hepatitis C virus (HCV) infection in a homogeneous

65 Fibrosis progression after acute hepatitis C virus (HCV) infection in human immunod

66 ness and cost-effectiveness of screening for acute hepatitis C virus (HCV) infection in human immunod

67 Spontaneous clearance of acute hepatitis C virus (HCV) infection is associated wi

68 appearance of neutralizing antibodies during acute hepatitis C virus (HCV) infection is associated wi

69 Acute hepatitis C virus (HCV) infection is often asympto

70 Acute hepatitis C virus (HCV) infection is rarely studie

71 Acute hepatitis C virus (HCV) infection is underdiagnose

72 Treatment of acute hepatitis C virus (HCV) infection leads to a susta

73 une responses during the first few months of acute hepatitis C virus (HCV) infection seem crucial for

74 guidelines now recommend that patients with acute hepatitis C virus (HCV) infection should be treate

75 Acute hepatitis C virus (HCV) infection was the final di

76 Historically, acute hepatitis C virus (HCV) infection was treated with

77 over, these cells were highly permissive for acute hepatitis C virus (HCV) infection, and persistent

78 e thought to be important for the control of acute hepatitis C virus (HCV) infection, but to date lit

79 In acute hepatitis C virus (HCV) infection, programmed deat

80 In the setting of acute hepatitis C virus (HCV) infection, robust HCV-spec

81 In studies of acute hepatitis C virus (HCV) infection, the early host

82 c liver disease may develop many years after acute hepatitis C virus (HCV) infection, the past incide

83 e early events that determine the outcome of acute hepatitis C virus (HCV) infection, we compared the

84 are the hallmark of spontaneous clearance of acute hepatitis C virus (HCV) infection, whereas compara

85 ics and evolution predict outcome of primary acute hepatitis C virus (HCV) infection.

86 therapy has not been adequately evaluated in acute hepatitis C virus (HCV) infection.

87 variation is a determinant of recovery from acute hepatitis C virus (HCV) infection; however, to dat

88 Sexually transmitted acute hepatitis C virus (HCV) infections (AHIs) have bee

89 estigation was to prospectively characterize acute hepatitis C virus (HCV) infections and to evaluate

90 States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined fr

91 Acute hepatitis C virus (HCV) is typically defined as ne

92 we hypothesized that early DAA treatment of acute hepatitis C virus (HCV) with DAAs may normalize mo

93 ered for 8, 12, or 24 weeks in patients with acute hepatitis C virus infection a total of 161 patient

94 Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, a

95 These findings indicate that, during acute hepatitis C virus infection in vivo, virus-specifi

96 ed virologic response rates in patients with acute hepatitis C virus infection, thus preventing devel

97 a total of 161 patients were identified with acute hepatitis C virus infection.

98 ther these observations indicate that during acute hepatitis C, virus evolution was driven primarily

99 Acute hepatitis C was associated with marked changes in

100 ks in addition to 14 untreated subjects with acute hepatitis C were prospectively followed.

101 and immunological studies on 7 patients with acute hepatitis C who received antiviral therapy and wer

102 Forty subjects with proven acute hepatitis C who received either PEG IFN-alpha plus